These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19925378)

  • 21. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Gulley JL; Wu S; Arlen PM; Dahut WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
    Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
    Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
    Saad F; Mulders P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
    Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
    Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
    Saad F; Colombel M
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bisphosphonate against patients with hormone refractory prostate cancer].
    Shinohara N
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():576-80. PubMed ID: 22208047
    [No Abstract]   [Full Text] [Related]  

  • 29. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.
    Fulfaro F; Leto G; Badalamenti G; Arcara C; Cicero G; Valerio MR; Di Fede G; Russo A; Vitale A; Rini GB; Casuccio A; Intrivici C; Gebbia N
    J Chemother; 2005 Oct; 17(5):555-9. PubMed ID: 16323446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse effects of bisphosphonates: current issues.
    Diel IJ; Bergner R; Grötz KA
    J Support Oncol; 2007; 5(10):475-82. PubMed ID: 18240669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
    Lein M; Wirth M; Miller K; Eickenberg HU; Weissbach L; Schmidt K; Haus U; Stephan C; Meissner S; Loening SA; Jung K
    Eur Urol; 2007 Nov; 52(5):1381-7. PubMed ID: 17321667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of zoledronic acid in pediatric cancer patients.
    August KJ; Dalton A; Katzenstein HM; George B; Olson TA; Wasilewski-Masker K; Rapkin LB
    Pediatr Blood Cancer; 2011 Apr; 56(4):610-4. PubMed ID: 21298747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.
    Serefoglu EC; Balbay MD
    Med Hypotheses; 2009 Sep; 73(3):387-8. PubMed ID: 19403241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
    Heidenreich A; Ohlmann CH
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):991-1005. PubMed ID: 15606328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
    J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
    Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
    [No Abstract]   [Full Text] [Related]  

  • 39. Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone metastases.
    Gaines KK
    Urol Nurs; 2002 Dec; 22(6):398-400. PubMed ID: 12593231
    [No Abstract]   [Full Text] [Related]  

  • 40. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial.
    Okegawa T; Higaki M; Matsumoto T; Kase H; Murata A; Noda K; Noda H; Asaoka H; Oshi M; Tomoishi J; Uchida H; Higashihara E; Nutahara K;
    Anticancer Res; 2014 Aug; 34(8):4415-20. PubMed ID: 25075079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.